CLOVIS ONCOLOGY INC's ticker is CLVS and the CUSIP is 189464100. A total of 184 filers reported holding CLOVIS ONCOLOGY INC in Q2 2015. The put-call ratio across all filers is 1.20 and the average weighting 0.6%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2016 | $66,197,000 | +38.8% | 1,490,258 | +12.7% | 0.01% | +20.0% |
Q3 2016 | $47,677,000 | +172.6% | 1,322,514 | +3.8% | 0.01% | +150.0% |
Q2 2016 | $17,487,000 | -24.0% | 1,274,534 | +6.3% | 0.00% | -20.0% |
Q1 2016 | $23,019,000 | -43.0% | 1,198,921 | +3.9% | 0.01% | -44.4% |
Q4 2015 | $40,390,000 | -64.5% | 1,153,986 | -6.6% | 0.01% | -69.0% |
Q3 2015 | $113,652,000 | +24.5% | 1,235,880 | +18.9% | 0.03% | +31.8% |
Q2 2015 | $91,317,000 | +15.4% | 1,039,109 | -2.5% | 0.02% | +15.8% |
Q1 2015 | $79,147,000 | +35.9% | 1,066,240 | +2.6% | 0.02% | +35.7% |
Q4 2014 | $58,221,000 | +33.8% | 1,039,661 | +8.4% | 0.01% | +16.7% |
Q3 2014 | $43,500,000 | +9.6% | 958,991 | +0.1% | 0.01% | +9.1% |
Q2 2014 | $39,675,000 | -33.6% | 958,092 | +11.1% | 0.01% | -38.9% |
Q1 2014 | $59,732,000 | +19.5% | 862,307 | +3.9% | 0.02% | +20.0% |
Q4 2013 | $50,003,000 | +11.1% | 829,654 | +12.1% | 0.02% | 0.0% |
Q3 2013 | $45,013,000 | +20.7% | 740,346 | +32.9% | 0.02% | +7.1% |
Q2 2013 | $37,305,000 | – | 556,957 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Versant Venture Management, LLC | 407,416 | $14,259,560,000 | 8.34% |
Palo Alto Investors LP | 3,547,719 | $124,170,000 | 6.91% |
Antipodean Advisors LLC | 1,268,658 | $44,403,000 | 6.48% |
Redmile Group, LLC | 1,795,936 | $62,858,000 | 4.70% |
HealthCor Management, L.P. | 1,525,000 | $53,375,000 | 3.24% |
PointState Capital LP | 3,503,900 | $122,637,000 | 3.12% |
NEA Management Company, LLC | 1,139,890 | $39,896,000 | 2.54% |
CLIFTON PARK CAPITAL MANAGEMENT, LLC | 612,500 | $21,438,000 | 2.44% |
PFM Health Sciences, LP | 2,078,440 | $72,745,000 | 2.21% |
Partner Investment Management, L.P. | 35,300 | $1,236,000 | 2.03% |